Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments

Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments

Saved in:

Bibliographic Details
Main Authors:	NICOLA SGHERZA, Anna Mestice, Angela Maria Vittoria Larocca, Pellegrino Musto
Format:	Article
Language:	English
Published:	PAGEPress Publications 2024-02-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	breakthrough SARS-CoV-2 infection, multiple myeloma, serological response
Online Access:	https://www.mjhid.org/mjhid/article/view/5618
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Humoral immune response after anti-SARS-CoV-2 vaccine “booster” dose in patients with monoclonal gammopathy of undetermined significance (MGUS)
by: NICOLA SGHERZA, et al.
Published: (2023-01-01)

BREAKTHROUGH ECONOMY: FEATURES OF FORMATION AND DEVELOPMENT IN RUSSIA
by: E. Bykovskaia, et al.
Published: (2019-11-01)

Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy
by: Sol Jin, et al.
Published: (2025-02-01)

The Dependence of Water and Gas Breakthrough on the Choice of Model Parameters in Naturally Fractured Reservoirs Using Sector and Full Reservoir Models
by: Barham Sabir Mahmood, et al.
Published: (2024-05-01)

Single-cell transcriptome atlas of peripheral immune features to Omicron breakthrough infection under booster vaccination strategies
by: Yuwei Zhang, et al.
Published: (2025-01-01)

Characteristics of humoral responses to the first coronavirus disease booster vaccine and breakthrough infection in central China: a multicentre, prospective, longitudinal cohort study
by: Junhong Xu, et al.
Published: (2025-01-01)

Oral manifestations of multiple myeloma – A systematic review
by: Padmajaa Krishnan, et al.
Published: (2024-06-01)

Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
by: Kara I. Cicero, et al.
Published: (2025-01-01)

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
by: Alberto L. Horenstein, et al.
Published: (2025-02-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

Does intelligent manufacturing promote a breakthrough in green innovation? Evidence from China
by: Xiangshu Dong, et al.
Published: (2025-01-01)

Chromothripsis in Treatment Resistance in Multiple Myeloma
by: Kyoung Joo Lee, et al.
Published: (2017-09-01)

Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
by: Dandan Gao, et al.
Published: (2025-01-01)

Study on the mechanism of gas migration and breakthrough in saturated bentonite considering the interface effect
by: Daoping Liu, et al.
Published: (2025-01-01)

Maternal-fetal cytokine profiles in acute SARS-CoV-2 “breakthrough” infection after COVID-19 vaccination
by: Claire H. Packer, et al.
Published: (2025-01-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

A Rare Case of Superior Mesenteric Artery Thrombosis in Multiple Myeloma
by: Jasminder Singh, et al.
Published: (2024-12-01)

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
by: Quane Zhang, et al.
Published: (2025-01-01)

Rapid Progression of Plasmacytoma to Multiple Myeloma after Cervical Laminectomy
by: Dudung Lupito, et al.
Published: (2024-12-01)

Incorporation and Effect of Arachidonic Acid on the Growth of Human Myeloma Cell Lines
by: V. Desplat, et al.
Published: (1999-01-01)

Blood absolute lymphocyte count and trajectory are important in understanding severe COVID-19
by: Catharine I. Paules, et al.
Published: (2025-01-01)

Evaluation of plasma cell sorting methods in multiple myeloma patients: flow cytometry versus magnetic beads
by: Yu Jeong Choi, et al.
Published: (2025-01-01)

Clinical Outcomes of Patients with Multiple Myeloma Presenting with Renal Failure
by: Joydeep Singh Vasant, et al.

Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study
by: Matthew A. Lee, et al.
Published: (2025-01-01)

Absolute Lymphocyte Count Is Not a Suitable Alternative to CD4 Count for Determining Initiation of Antiretroviral Therapy in Fiji
by: Dashika A. Balak, et al.
Published: (2014-01-01)

Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis
by: Xuejie Gao, et al.
Published: (2025-01-01)

Prognostic correlation analysis of multiple myeloma based on HALP score of peripheral blood before chemotherapy
by: CHEN Min, et al.
Published: (2025-01-01)

Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation
by: Yanhua Yue, et al.
Published: (2025-12-01)

Boanmycin overcomes bortezomib resistance by inducing DNA damage and endoplasmic reticulum functional impairment in multiple myeloma
by: Jin-Xing Wang, et al.
Published: (2025-01-01)

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic
by: Ondrej Šušol, et al.
Published: (2024-12-01)

The association between the dietary inflammatory index and multiple myeloma: a case–control study
by: Hoda Zahedi, et al.
Published: (2025-01-01)

Metabolomics approach reveals key plasma biomarkers in multiple myeloma for diagnosis, staging, and prognosis
by: Xiaoxue Wang, et al.
Published: (2025-02-01)

Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
by: Fahad Alshammari, et al.
Published: (2025-12-01)

Autologous Hematopoietic Cell Transplant as an Effective Treatment Modality for Systemic Sclerosis and Multiple Myeloma
by: Memon H, et al.
Published: (2025-01-01)

Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group
by: Anna Waszczuk-Gajda, et al.
Published: (2020-04-01)

Detection of new single nucleotide polymorphisms in plasma cells carcinoma (myeloma) by polymerase chain reaction–single strand conformation polymorphism and sequencing technical methods
by: Sarah K. Obayes, et al.
Published: (2024-01-01)

Deguelin inhibits the proliferation of human multiple myeloma cells by inducing apoptosis and G2/M cell cycle arrest: Involvement of Akt and p38 MAPK signalling pathway
by: Sun Kening, et al.
Published: (2024-03-01)

Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in US Veterans with rheumatoid arthritis
by: Kate Tokareva, et al.
Published: (2025-01-01)

Knowledge, attitude and practice towards multiple myeloma among medical staff in Enshi Region
by: Luping Zou, et al.
Published: (2025-01-01)

High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment
by: Halina Urbanska-Rys, et al.
Published: (2003-01-01)